Content
Frontiers of Medicine >> 2019, Volume 13, Issue 3 doi: 10.1007/s11684-018-0639-7
Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety
. Peking University People’s Hospital, Beijing 100044, China;.. Fujian Medical University Union Hospital, Fuzhou 350004, China;.. The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China;.. The First Affiliated Hospital of The College of Medicine, Zhejiang University, Hangzhou 310058, China;.. Guangzhou Nanfang Hospital, Guangzhou 510515, China;.. Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;.. West China Hospital, Sichuan University, Chengdu 610041, China;.. The First Affiliated Hospital of Soochow University, Suzhou 215006, China;.. Changhai Hospital of Shanghai, Shanghai 200433, China;.. The Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China
Abstract
Keywords
chronic myeloid leukemia (CML) ; dasatinib ; tyrosine kinase inhibitor ; long-term follow-up
Content